Señalización JAK / STAT
Los inhibidores de la señalización JAK/STAT son compuestos que interrumpen la vía de la cinasa Janus (JAK) y del transductor y activador de la transcripción (STAT), la cual está involucrada en la señalización de citoquinas, el crecimiento celular y la respuesta inmunitaria. Estos inhibidores son herramientas importantes para estudiar la regulación de esta vía y su papel en diversas enfermedades, como el cáncer, los trastornos inmunitarios y las condiciones inflamatorias. Los inhibidores de JAK/STAT también están siendo desarrollados como terapias dirigidas para estas enfermedades. En CymitQuimica, ofrecemos una amplia selección de inhibidores de alta calidad de la señalización JAK/STAT para apoyar su investigación en biología molecular, oncología e inmunología.
Subcategorías de "Señalización JAK / STAT"
Se han encontrado 321 productos de "Señalización JAK / STAT"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
(Z)-LFM-A13
CAS:<p>(Z)-LFM-A13(IC50=2.5 μM), a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases, such as JAK1, JAK2, HCK, EGFR, and IRK.</p>Fórmula:C11H8Br2N2O2Pureza:99.88%Forma y color:SolidPeso molecular:360AT9283
CAS:<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Fórmula:C19H23N7O2Pureza:99.83% - 99.98%Forma y color:SolidPeso molecular:381.43Pim1/AKK1-IN-1
CAS:<p>Pim1/AKK1-IN-1: LKB1/AAK1 inhibitor with Kd 35/53/75/380 nM for Pim1/AKK1/MST2/LKB1, also targets MPSK1, TNIK.</p>Fórmula:C20H13N5OPureza:97.03% - 98.69%Forma y color:SolidPeso molecular:339.35CEP-33779
CAS:<p>CEP-33779 is a novel and selective inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.</p>Fórmula:C24H26N6O2SPureza:98.24% - ≥95%Forma y color:SolidPeso molecular:462.57Pacritinib
CAS:<p>Pacritinib (SB1518) (SB1518) is an effective and specific inhibitor of JAK2 and FLT3 (IC50: 23/22 nM, in cell-free assays).</p>Fórmula:C28H32N4O3Pureza:99.25% - 99.49%Forma y color:SolidPeso molecular:472.58Baricitinib phosphate
CAS:<p>Baricitinib phosphate (INCB028050) is a selective orally bioavailable JAK1/JAK2 inhibitor.</p>Fórmula:C16H20N7O6PSPureza:99.4% - 99.82%Forma y color:SolidPeso molecular:469.41Momelotinib HCl
CAS:<p>Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.</p>Fórmula:C23H24Cl2N6O2Forma y color:SolidPeso molecular:487.38SMI-16a
CAS:<p>SMI-16a (PIM1/2 Kinase Inhibitor VI) , a cell-permeable thiazolidinedione compound, acts as an effective, ATP-competitive inhibitor against Pim-1/2 kinases (</p>Fórmula:C13H13NO3SPureza:99.99%Forma y color:SolidPeso molecular:263.31Gandotinib
CAS:<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Fórmula:C23H25ClFN7OPureza:99.33% - 99.86%Forma y color:SolidPeso molecular:469.94Filgotinib
CAS:<p>Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.</p>Fórmula:C21H23N5O3SPureza:98.03% - ≥95%Forma y color:SolidPeso molecular:425.52,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide
CAS:<p>2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide (GDC046), a potent lead analog, has good kinase selectivity and physicochemical properties.</p>Fórmula:C16H13Cl2N3O2Pureza:98.77%Forma y color:SolidPeso molecular:350.2JAK-IN-5 hydrochloride
CAS:<p>JAK-IN-5 hydrochloride is a JAK inhibitor [1].</p>Fórmula:C27H32ClFN6OForma y color:SolidPeso molecular:511.03AZD-1480
CAS:<p>AZD1480: JAK2 inhibitor, IC50 0.26 nM; selective vs Tyk2, JAK3; less on JAK1. Used in solid tumors, PPV, PMF, ET trials.</p>Fórmula:C14H14ClFN8Pureza:98.25% - 99.47%Forma y color:SolidPeso molecular:348.77Oclacitinib
CAS:<p>Oclacitinib (PF-03394197)(PF03394197) is a potent and selective JAKs inhibitor with IC50 of 10-99 nM; not inhibit a panel of 38 non-JAK kinases (IC50 's > 1000</p>Fórmula:C15H23N5O2SPureza:98% - 98.45%Forma y color:White To Off-White SolidPeso molecular:337.44Fedratinib
CAS:<p>Fedratinib (TG-101348) (TG101348) is an ATP-competitive inhibitor of JAK2 (IC50: 3 nM) with significantly less potent activity against JAK3.</p>Fórmula:C27H36N6O3SPureza:97.31% - 99.96%Forma y color:SolidPeso molecular:524.68Tofacitinib Citrate
CAS:<p>Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).</p>Fórmula:C22H28N6O8Pureza:99.19% - 99.75%Forma y color:SolidPeso molecular:504.49(Z)-SMI-4a
CAS:<p>(Z)-SMI-4a (TCS PIM-1 4a) is a selective ATP-competitive Pim-1 kinase inhibitor with an IC50 of 21 nM.</p>Fórmula:C11H6F3NO2SPureza:97.66% - 99.93%Forma y color:SolidPeso molecular:273.23Oclacitinib maleate
CAS:<p>Oclacitinib maleate is a selective JAK inhibitor (IC50: 10-99 nM; JAK1 cytokines: 36-249 nM), with no effect on 38 non-JAK kinases.</p>Fórmula:C15H23N5O2S·C4H4O4Pureza:99.17%Forma y color:SolidPeso molecular:453.51Ruxolitinib (S enantiomer)
CAS:<p>Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.</p>Fórmula:C17H18N6Pureza:99.37% - 99.79%Forma y color:SolidPeso molecular:306.36HJ-PI01
CAS:<p>HJ-PI01 (HJ-PI01) is a Pim-2 inhibitor. HJ-PI01 (HJ-PI01) induces apoptosis and autophagic cell death in triple-negative human breast cancer.</p>Fórmula:C14H11NO2Pureza:98.92%Forma y color:SolidPeso molecular:225.24SAR-20347
CAS:<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Fórmula:C21H18ClFN4O4Pureza:98.99% - 99.77%Forma y color:SolidPeso molecular:444.84Fosifidancitinib
CAS:<p>Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.</p>Fórmula:C21H21FN5O7PPureza:99.54%Forma y color:SolidPeso molecular:505.39Solcitinib
CAS:<p>Solcitinib (GLPG-0778), a JAK1 inhibitor, may treat psoriasis, ulcerative colitis, and lupus.</p>Fórmula:C22H23N5O2Pureza:99.61% - 99.82%Forma y color:SolidPeso molecular:389.45Ruxolitinib
CAS:<p>Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.</p>Fórmula:C17H18N6Pureza:99.4% - >99.99%Forma y color:SolidPeso molecular:306.36Ritlecitinib
CAS:<p>Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.</p>Fórmula:C15H19N5OPureza:98.82% - 99.92%Forma y color:SolidPeso molecular:285.34PF-06651600 malonate
CAS:<p>PF-06651600 is a potent and selective JAK3 inhibitor.</p>Fórmula:C18H23N5O5Forma y color:SolidPeso molecular:389.41Tofacitinib
CAS:<p>Tofacitinib (Tasocitinib) is an orally Janus kinase inhibitor. Tofacitinib is used for the treatment of rheumatoid arthritis. Cost effective and quality assured.</p>Fórmula:C16H20N6OPureza:99% - >99.99%Forma y color:SolidPeso molecular:312.37Gusacitinib HCl
CAS:<p>Gusacitinib (ASN-002/EN-3351), a potent SYK/JAK inhibitor, has strong antitumor activity in various cancers.</p>Fórmula:C24H29ClN8O2Forma y color:SolidPeso molecular:497Itacitinib
CAS:<p>Itacitinib (INCB039110) is an orally bioavailable inhibitor of Janus-associated kinase 1 (JAK1) with potential antineoplastic activity.</p>Fórmula:C26H23F4N9OPureza:96.4% - 99.5%Forma y color:SolidPeso molecular:553.51SGI-1776
CAS:<p>SGI-1776 (Pim-Kinase Inhibitor IX) has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.</p>Fórmula:C20H22F3N5OPureza:99.3% - >99.99%Forma y color:SolidPeso molecular:405.42WHI-P97
CAS:<p>WHI-P97 is a rationally designed potent inhibitor of JAK-3.</p>Fórmula:C16H13Br2N3O3Pureza:99.93%Forma y color:SolidPeso molecular:455.1Pyridone 6
CAS:<p>Pyridone 6, a selective JAK1/2/3 and Tyk2 inhibitor with IC50s: JAK1=15 nM, JAK2=1 nM, JAK3 (Ki=5 nM), Tyk2=1 nM; weakly binds other kinases (130 nM-10 μM).</p>Fórmula:C18H16FN3OPureza:97.1% - 98.74%Forma y color:SolidPeso molecular:309.34WHI-P97 HCl
<p>WHI-P97 HCl is a potent and selective JAK-3 inhibitor.</p>Fórmula:C16H14Br2ClN3O3Pureza:99.49%Forma y color:SolidPeso molecular:491.56TCS PIM-1 1
CAS:<p>TCS PIM-1 1 (SC 204330) is a potent ATP-competitive inhibitor of Pim-1 kinase with an IC50 of 50 nM, selective over MEK1/2 and Pim-2.</p>Fórmula:C18H11BrN2O2Pureza:97% - 97.98%Forma y color:SolidPeso molecular:367.2WHI-P154
CAS:<p>WHI-P154 (Jak3 inhibitor ii) is a potent JAK3 inhibitor.</p>Fórmula:C16H14BrN3O3Pureza:98% - 99.67%Forma y color:SolidPeso molecular:376.2SC99
CAS:<p>SC99 inhibits JAK2-STAT3, reducing STAT3 genes, platelet activity, and has anti-myeloma, anti-thrombotic effects.</p>Fórmula:C15H8Cl2FN3OPureza:99.56%Forma y color:SolidPeso molecular:336.15Ruxolitinib phosphate
CAS:<p>Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Cost-effective and quality-assured.</p>Fórmula:C17H21N6O4PPureza:98% - >99.99%Forma y color:SolidPeso molecular:404.36GLPG0634 analog
CAS:<p>GLPG0634 analog (GLPG0634 analogue) is a specific JAK1 inhibitor with IC50 of 10/28/810/116 nM for JAK1/2/3 and TYK2, respectively.</p>Fórmula:C23H18N6O2Pureza:99.52% - >99.99%Forma y color:SolidPeso molecular:410.43Baricitinib
CAS:<p>Baricitinib (INCB028050) is an orally JAK1 and JAK2 inhibitor. Baricitinib has anti-inflammatory and anti-tumor activity. Cost-effective and quality-assured.</p>Fórmula:C16H17N7O2SPureza:99% - >99.99%Forma y color:SolidPeso molecular:371.42GDC-0214
CAS:<p>GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).</p>Fórmula:C28H28ClF2N9O3Pureza:99.75%Forma y color:SolidPeso molecular:612.03Peramivir Trihydrate
CAS:<p>Peramivir Trihydrate (RWJ-270201) is a neuraminidase inhibitor (IC50: 0.09 nM) which prevents normal processing of virus particles such that virus particles are</p>Fórmula:C15H28N4O4·3H2OPureza:99.52% - ≥95%Forma y color:SolidPeso molecular:382.45TG101209
CAS:<p>TG101209 is a selective JAK2 inhibitor with IC50 of 6 nM.</p>Fórmula:C26H35N7O2SPureza:99% - >99.99%Forma y color:SolidPeso molecular:509.67NVP-BSK805 trihydrochloride
CAS:<p>NVP-BSK805 trihydrochloride inhibits JAK2 (0.48 nM IC50); also affects JAK1, JAK3, TYK2.</p>Fórmula:C27H31Cl3F2N6OForma y color:SolidPeso molecular:599.93(E/Z)-Zotiraciclib
CAS:<p>(E/Z)-Zotiraciclib ((E/Z)-TG02) inhibits CDK2, JAK2, and FLT3 effectively with IC50s of 13, 73, and 56 nM, respectively.</p>Fórmula:C23H24N4OPureza:97.75% - 99.92%Forma y color:SolidPeso molecular:372.46G5-7
CAS:<p>G5-7 is an oral JAK2 inhibitor targeting EGFR/STAT3 phosphorylation with potential for glioma research.</p>Fórmula:C22H19F2NO3Pureza:97.3%Forma y color:SolidPeso molecular:383.39RO8191
CAS:<p>RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.</p>Fórmula:C14H5F6N5OPureza:98% - 98.85%Forma y color:SolidPeso molecular:373.21Fedratinib hydrochloride hydrate
CAS:<p>Fedratinib hydrochloride hydrate (SAR 302503 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor.</p>Fórmula:C27H40Cl2N6O4SPureza:98.96% - 99.87%Forma y color:SolidPeso molecular:615.61Decernotinib
CAS:<p>Decernotinib (VRT-831509)(VX-509; VRT-831509) is a potent and selective Janus kinase 3 (JAK3) inhibitor with Ki of 2.5 nM; IC50 is 50-170 nM in cellular assays.</p>Fórmula:C18H19F3N6OPureza:99.28% - >99.99%Forma y color:SolidPeso molecular:392.38AMG-47a
CAS:<p>AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.</p>Fórmula:C29H28F3N5O2Pureza:98%Forma y color:SolidPeso molecular:535.56JAK3-IN-6
CAS:<p>JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM</p>Fórmula:C19H18N4O3Pureza:99.94% - 99.94%Forma y color:SolidPeso molecular:350.37Niclosamide sodium
CAS:<p>Niclosamide (BAY2353) sodium: oral antihelminthic, STAT3 inhibitor (IC50 0.25 μM), anti-cancer, and DNA replication blocker.</p>Fórmula:C13H7Cl2N2NaO4Forma y color:SolidPeso molecular:349.1RGB-286638 free base
CAS:<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Fórmula:C29H35N7O4Pureza:98% - 99.91%Forma y color:SolidPeso molecular:545.63FLLL32
CAS:<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Fórmula:C28H32O6Pureza:97% - 97.90%Forma y color:SolidPeso molecular:464.55Abrocitinib
CAS:<p>Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).</p>Fórmula:C14H21N5O2SPureza:99.09% - 99.91%Forma y color:SolidPeso molecular:323.41JANEX-1
CAS:<p>JANEX-1: cell-permeable, reversible Jak3 inhibitor (IC50: 78 μM), ATP-competitive, selective; weak on JAK1/2, Zap/Syk, SRC.</p>Fórmula:C16H15N3O3Pureza:98% - 99.81%Forma y color:SolidPeso molecular:297.31STAT5-IN-1
CAS:<p>STAT5-IN-1 (STAT5 Inhibitor) is a cell-permeable inhibitor which suppresses Stat5 via binding to the SH2 domain.</p>Fórmula:C16H11N3O3Pureza:99.44% - ≥95%Forma y color:SolidPeso molecular:293.28AZD1208
CAS:<p>AZD1208 is a novel, orally bioavailable, highly selective PIM kinase inhibitor with single nanomolar potency against all three PIM kinases.</p>Fórmula:C21H21N3O2SPureza:97.24% - 99.83%Forma y color:SolidPeso molecular:379.48Hispidulin
CAS:<p>Hispidulin, a natural flavone with a broad spectrum of biological activities, is a Pim-1 inhibitor (IC50: 2.71 μM).</p>Fórmula:C16H12O6Pureza:98.53% - 99.87%Forma y color:SolidPeso molecular:300.26Pacritinib hydrochloride
CAS:<p>Pacritinib HCl: strong JAK2/Wild-type & JAK2V617F inhibitor (IC50: 23/19 nM), used in AML & MF research.</p>Fórmula:C28H32N4O3·xClHForma y color:SolidBrevilin A
CAS:<p>Brevilin A, a sesquiterpene from Centipeda minima, hinders JAK and blocks STAT3 (IC50=10.6μM), inducing apoptosis and autophagy in cancer cells.</p>Fórmula:C20H26O5Pureza:99.97% - >99.99%Forma y color:SolidPeso molecular:346.42WDR5-0103 hydrochloride[890190-22-4(free base)]
<p>WDR5-0103 hydrochloride[890190-22-4(free base)] (WD-Repeat Protein 5-0103) is an effective and specific WD repeat-containing protein 5 (WDR5) antagonist (Kd:</p>Fórmula:C21H26ClN3O4Pureza:99.66%Forma y color:SolidPeso molecular:419.9Ritlecitinib tosylate
CAS:<p>Ritlecitinib (PF-06651600) is a potent, selective JAK3 inhibitor with proven in vivo efficacy, low clearance, and has undergone clinical trials.</p>Fórmula:C22H27N5O4SForma y color:SolidPeso molecular:457.549AZ960
CAS:<p>AZ960 is an effective ATP competitive JAK2 inhibitor (IC50/Ki: <3 nM and0.45 nM).</p>Fórmula:C18H16F2N6Pureza:96.02% - 98.51%Forma y color:SolidPeso molecular:354.36Cerdulatinib
CAS:<p>Cerdulatinib (PRT2070) is an novel oral dual Syk/JAK inhibitor.</p>Fórmula:C20H27N7O3SPureza:98.74% - 99.49%Forma y color:SolidPeso molecular:445.54Upadacitinib
CAS:<p>Upadacitinib (ABT-494), a selective JAK1 inhibitor, is researched for autoimmune diseases; IC50: 43 nM.</p>Fórmula:C17H19F3N6OPureza:98.96% - 99.94%Forma y color:SolidPeso molecular:380.37Atractylenolide I
CAS:<p>Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.</p>Fórmula:C15H18O2Pureza:97.55% - 99.92%Forma y color:SolidPeso molecular:230.3CX-6258 hydrochloride
CAS:<p>CX-6258 hydrochloride (Pim-Kinase Inhibitor X) is an effective, orally efficacious Pim1/2/3 kinase inhibitor (IC50: 5/25/16 nM).</p>Fórmula:C26H24ClN3O3·HClPureza:96.03% - 98.60%Forma y color:SolidPeso molecular:498.4Cerdulatinib hydrochloride
CAS:<p>Cerdulatinib hydrochloride is an oral tyrosine kinase inhibitor targeting JAK1/2/3, TYK2, Syk, and 19 others with IC50 < 200 nM.</p>Fórmula:C20H28ClN7O3SPureza:99.85%Forma y color:SolidPeso molecular:482GS-829845
CAS:<p>GS-829845 is a JAK1 inhibitor, the main component of the active metabolite of Filgotinib, which is approximately 10-fold less potent and has a longer half-life</p>Fórmula:C17H19N5O2SPureza:99.93%Forma y color:SolidPeso molecular:357.43Golotimod
CAS:<p>Golotimod (SCV 07) is an antimicrobial active dipeptide with immunomodulatory activity for the study of recurrent genital herpes simplex virus 2 infections.</p>Fórmula:C16H19N3O5Pureza:99.88% - 99.98%Forma y color:SolidPeso molecular:333.34NVP-BSK805
CAS:<p>NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.</p>Fórmula:C27H28F2N6OPureza:98%Forma y color:SolidPeso molecular:490.55Solrikitug
CAS:<p>Solrikitug,Anti-CRLF2 humanized IgG1κ monoclonal antibody.</p>Pureza:95%Forma y color:LiquidTLC1566-0618
CAS:<p>TLC1566-0618 shows antitumor activity and targets stat.</p>Fórmula:C20H15NO3S3Pureza:98%Forma y color:SolidPeso molecular:413.53(3S,4S)-Tofacitinib
CAS:<p>(3S,4S)-Tofacitinib, a less active enantiomer of tofacitinib, is a Janus kinases inhibitor.</p>Fórmula:C16H20N6OPureza:98%Forma y color:SolidPeso molecular:312.37Golotimod TFA
CAS:<p>Golotimod TFA (SCV 07 TFA) is a dipeptide exhibiting immunomodulatory and antibacterial activity, alleviates radiation-induced oral mucositis.</p>Fórmula:C18H20F3N3O7Pureza:98%Forma y color:SoildPeso molecular:447.36ZM39923
CAS:<p>ZM39923 is a JAK3 inhibitor (pIC50: 7.1). ZM39923 also effectively inhibits tissue transglutaminase (IC50: 10 nM).</p>Fórmula:C23H25NOPureza:98%Forma y color:SolidPeso molecular:331.45SD-1029
CAS:<p>SD-1029 is a JAK2 inhibitor and a novel Stat3 activation inhibitor that inhibits Stat3 phosphorylation and JAK-STAT signaling.</p>Fórmula:C25H32Br2Cl2N2O3Forma y color:SolidPeso molecular:639.25K00135
CAS:<p>K00135 (IMIDAZOPYRIDAZIN 1) is a selective inhibitor of Pim kinases and can be used in studies about gastric cancer and antileukemic therapeutics.</p>Fórmula:C18H18N4OPureza:98.16%Forma y color:SolidPeso molecular:306.36JAK-IN-11
CAS:<p>JAK-IN-11 (R-348) is a potent and selective inhibitor of JAK, has the potential for the skin disorders treatment.</p>Fórmula:C23H22FN5O4SPureza:99.75%Forma y color:SolidPeso molecular:483.52CX-6258
CAS:<p>CX-6258 is an orally valid Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor. It has good biological activity and kinase specificity.</p>Fórmula:C26H24ClN3O3Pureza:97.46%Forma y color:SolidPeso molecular:461.94JAK-IN-20
CAS:<p>JAK-IN-20: potent oral JAK1,2,3 inhibitor with IC50s 7, 5, 14 nM respectively, good pharmacokinetics, anti-inflammatory in vivo.</p>Fórmula:C28H30FN7O2Forma y color:SolidPeso molecular:515.58Niclosamide monohydrate
CAS:<p>Niclosamide Monohydrate is used for the treatment of most tapeworm infections by inhibiting DNA replication.</p>Fórmula:C13H10Cl2N2O5Pureza:98%Forma y color:SolidPeso molecular:345.14Peficitinib hydrochloride
CAS:<p>Peficitinib HCl (ASP015K) is an oral JAK inhibitor with IC50s: JAK1 (3.9 nM), JAK2 (5.0 nM), JAK3 (0.7 nM), Tyk2 (4.8 nM).</p>Fórmula:C18H23ClN4O2Forma y color:SolidPeso molecular:362.86TK4b
CAS:<p>TK4b, a JAK inhibitor, targets leukemia/lymphoid diseases, with IC50s: 18.42 nM (JAK3) & 19.40 nM (JAK2).</p>Fórmula:C21H22N2O2Forma y color:SolidPeso molecular:334.41TK4g
CAS:<p>TK4g, a potent JAK inhibitor, has IC50s of 12.61 nM (JAK2) & 15.80 nM (JAK3); promising for lymphoid diseases & leukemia research.</p>Fórmula:C19H19N3O4SForma y color:SolidPeso molecular:385.44JAK-2/3-IN-2
CAS:<p>JAK-2/3-IN-2 (Compound 3h) is a potent JAK2 & JAK3 inhibitor with IC50s of 23.85 nM (JAK2) & 18.9 nM (JAK3).</p>Fórmula:C19H19ClN2OSForma y color:SolidPeso molecular:358.89XZH-5
CAS:<p>XZH-5 is an inhibitor of STAT3.</p>Fórmula:C22H25F6N5O4Pureza:98%Forma y color:SolidPeso molecular:537.46JAK-IN-14
CAS:<p>JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.</p>Fórmula:C19H15FN4OPureza:98.27%Forma y color:SolidPeso molecular:334.35TyK2-IN-2
CAS:<p>TyK2-IN-2 is a selective inhibitor of TYK2 (IC50s: 7 nM, 0.1 μM, and 0.05 μM for TYK2 JH2, IL-23, and IFNα).</p>Fórmula:C16H18N6OPureza:98%Forma y color:SolidPeso molecular:310.35JAK-IN-18
CAS:<p>"JAK-IN-18: potent JAK inhibitor for eye, skin, respiratory disease research (WO2018204238A1, comp 1)."</p>Fórmula:C27H28F2N6O3Forma y color:SolidPeso molecular:522.55JAK3-IN-12
CAS:<p>JAK3-IN-12 (compound 15k) is a potent inhibitor of JAK3 (IC50: 9.5 nM) and can be used in the study of rheumatoid arthritis.</p>Fórmula:C19H19N5O4SForma y color:SolidPeso molecular:413.45Tyk2-IN-5
CAS:<p>Tyk2-IN-5 is a selective and orally active inhibitor of Tyk2 JH2 (Ki: 0.086 nM for Tyk2 JH2; IC50: 25 nM for IFNα).</p>Fórmula:C21H19FN8O2Pureza:98%Forma y color:SolidPeso molecular:434.43Tyk2-IN-7
CAS:<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Fórmula:C18H15D3N6O3SPureza:98%Forma y color:SolidPeso molecular:401.46MS-1020
CAS:<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Fórmula:C21H18N2O3Pureza:98%Forma y color:SolidPeso molecular:346.381,2,3,4,5,6-Hexabromocyclohexane
CAS:<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Fórmula:C6H6Br6Pureza:98%Forma y color:SolidPeso molecular:557.54OICR-0547
CAS:<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>Fórmula:C28H29F3N4O4Pureza:98%Forma y color:SolidPeso molecular:542.55JAK3-IN-9
CAS:<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Fórmula:C17H23N5O4SForma y color:SolidPeso molecular:393.46EP009
CAS:<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Fórmula:C14H24O2Forma y color:SolidPeso molecular:224.34INCB16562
CAS:<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Fórmula:C19H11Cl2N5Forma y color:SolidPeso molecular:380.23
![WDR5-0103 hydrochloride[890190-22-4(free base)]](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FT5140.webp&w=3840&q=75)
